Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Abstract

This cohort study examines the association of concomitant genetics alterations with response to treatment with epidermal growth factor receptor tyrosine kinase inhibitors among patients with EGFR-mutant advanced non–small cell lung cancer.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Zhang has received research support from AstraZeneca, Eli Lilly, and Roche. No other disclosures were reported.

Figures

Figure.. Genetic Alteration Profile of Circulating Tumor DNA (ctDNA) From Tyrosine Kinase Inhibitor (TKI)–Naive Patients With EGFR-Mutant Non–Small Cell Lung Cancer (NSCLC) and Its Association With Survival

A, Genetic mutations identified by targeted next-generation sequencing in the plasma of 58 patients with NSCLC harboring EGFR mutation in tumor tissue. The sequencing covers 49 cancer-related genes and involves 2659 Catalogue of Somatic Mutations in Cancer (COSMIC) mutations. B, Kaplan-Meier curves of progression-free survival (PFS) in patients whose ctDNA had concomitant mutations compared with those without concomitant mutations. C, Kaplan-Meier curves of overall survival (OS) in patients whose ctDNA had concomitant mutations compared with those without concomitant mutations. ARMS indicates amplification refractory mutation system; CR, complete response; del, deletion; EGFR, epidermal growth factor receptor; HR, hazard ratio; NR, not reached; PD, progressive disease; PR, partial response; SD, stable disease; seq, sequencing; and VAF, variant allele frequency.